Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF -Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Michael B AtkinsSandra J LeeBartosz ChmielowskiAhmad A TarhiniGary I CohenThach-Giao TruongHelen H MoonDiwakar DavarMark Allen O'RourkeJoseph J StephensonBrendan D CurtiWalter J UrbaJoanna M BrellPauline FunchainKari L KendraAlexandra P IkeguchiAnthony JaslowskiCharles L BaneMark A TaylorMadhuri BajajRobert M ConryRobert J EllisTheodore F LoganNoel LaudiJeffrey A SosmanDavid G CrockettAndrew L PecoraIan J OkazakiSowjanya RegantiSunandana ChandraSamantha GuildHelen X ChenHoward Z StreicherJedd D WolchokAntoni RibasJoanne M JeterPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Combination nivolumab/ipilimumab followed by BRAF and MEK inhibitor therapy, if necessary, should be the preferred treatment sequence for a large majority of patients.